A- A A+

Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users.

Baandrup L, Ebdrup BH, Rasmussen JØ, Lindschou J, Gluud C, Glenthøj BY.

Cochrane Database Syst Rev. 2018 Mar 15;3:CD011481. doi: 10.1002/14651858.CD011481.pub2. Review.

Abstract

http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD011481.pub2/abstract;jsessionid=E989FA8D95320BBB28282A068726E3B1.f02t02

The Effects of Concurrent Prescription of Benzodiazepines for People Undergoing Opioid Maintenance Treatment: Systematic Review [Internet].

Ding KY, Mosdøl A, Hov L, Staumann GH, Vist GE.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2016 Dec 23.

https://www.fhi.no/en/publ/2016/effekten-av-samtidig-forskrivning-av-benzodiazepiner-for-personer-i-legemid/

Benzodiazepines.

Bounds CG, Nelson VL.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2017 Jun-.
2017 Nov 26.

https://www.ncbi.nlm.nih.gov/books/NBK470159/

Co-prescription of opioids with benzodiazepine and other co-medications among opioid users: differential in opioid doses.

Zin CS, Ismail F.

J Pain Res. 2017 Jan 25;10:249-257. doi: 10.2147/JPR.S122853.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279838/

Benzodiazepine drug use and cancer risk: a dose-response meta analysis of prospective cohort studies.

Zhang T, Yang X, Zhou J, Liu P, Wang H, Li A, Zhou Y.

Oncotarget. 2017 Oct 19;8(60):102381-102391. doi: 10.18632/oncotarget.22057.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731963/

The influence of hospitalisation on the initiation, continuation and discontinuation of benzodiazepines and Z-drugs - an observational study.

Grimmsmann T, Harden M, Fiß T, Himmel W.

Swiss Med Wkly. 2018 Feb 14;148:w14590. doi: 10.4414/smw.2018.14590.

https://smw.ch/article/doi/smw.2018.14590

Benzodiazepine maintenance for alcohol dependence: A case series.

Kattimani S, Bharadwaj B, Arun AB.

J Family Med Prim Care. 2017 Apr-Jun;6(2):431-433. doi: 10.4103/2249-4863.220038.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749099/

Toxicity, Benzodiazepine.

Kang M, Ghassemzadeh S.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
2018 Jan 31. PMID: 29489152

https://www.ncbi.nlm.nih.gov/books/NBK482238/

Is misuse of benzodiazepines among high-risk drug users an overlooked public health issue?

Dominique Lopez, Lisbon Addictions 2017, Second European Conference on Addictive Behaviours and Dependencies, Lissabon, 24.-26.10.2017

http://www.emcdda.europa.eu/system/files/attachments/6815/12H45_2_Dominique Lopez.pptx

Our Other Prescription Drug Problem

Anna Lembke, M.D., Jennifer Papac, M.D., and Keith Humphreys, Ph.D.

N Engl J Med 2018; 378:693-695, DOI: 10.1056/NEJMp1715050

http://www.nejm.org/doi/full/10.1056/NEJMp1715050

Evaluating the impact of prescribed versus non-prescribed benzodiazepine use in opioid substitution therapy: Results from a population-based retrospective cohort study

Joseph K. Eibl, Lisbon Addictions 2017, Second European Conference on Addictive Behaviours and Dependencies, Lissabon, 24.-26.10.2017

http://www.emcdda.europa.eu/system/files/attachments/6779/11H30_5_Joseph Eibl.pptx

Benzodiazepine: Anstieg der Todesfälle in den USA

Palo Alto – Droht den USA nach der Opioid-Epidemie bereits die nächste iatrogen mitverantwortete Drogenkrise? US-Mediziner weisen in einem Perspektiv-Artikel im New England Journal of Medicine (2018; 378: 693-595) auf eine steigende Zahl von Todesfällen durch Benzodiazepin-Überdosierungen hin, für die sie eine unkritische Verordnung der Schlaf- und Beruhigungsmittel verantwortlich machen. (aerzteblatt.de, 26.02.2018)

https://www.aerzteblatt.de/nachrichten/89469/Benzodiazepine-Anstieg-der-Todesfaelle-in-den-USA

Effectiveness of Benzodiazepine Receptor Agonists in the Treatment of Insomnia: An Examination of Response and Remission Rates

Vivek Pillai, PhD, Thomas Roth, PhD, Timothy Roehrs, PhD, Kenneth Moss, MD, Edward L. Peterson, PhD, Christopher L. Drake, PhD;

Sleep, Volume 40, Issue 2, 1 February 2017, zsw044, org/10.1093/sleep/zsw044

https://academic.oup.com/sleep/article-lookup/doi/10.1093/sleep/zsw044

Cardiovascular effects of methadone and concomitant use of diazepam during methadone maintenance treatment induction: low concentration risk.

Mijatović V, Samojlik I, Petković S, Vukmirović S, Uvelin A, Dickov A.

Expert Opin Drug Saf. 2017 Dec;16(12):1323-1328. doi: 10.1080/14740338.2017.1382470.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/28934555

Based on our additional review, the U.S. Food and Drug Administration (FDA) is advising that the opioid addiction medications buprenorphine and methadone should not be withheld from patients taking benzodiazepines or other drugs that depress the central nervous system (CNS). The combined use of these drugs increases the risk of serious side effects; however, the harm caused by untreated opioid addiction can outweigh these risks. Careful medication management by health care professionals can reduce these risks. We are requiring this information to be added to the buprenorphine and methadone drug labels along with detailed recommendations for minimizing the use of medication-assisted treatment (MAT) drugs and benzodiazepines together. (FDA – U.S. Food&Drug Administration, 20.09.2017)

https://www.fda.gov/Drugs/DrugSafety/ucm575307.htm

Outpatient, combined use of opioid and benzodiazepine medications in the United States, 1993-2014.

Hirschtritt ME, Delucchi KL, Olfson M.

Prev Med Rep. 2017 Dec 21;9:49-54. doi: 10.1016/j.pmedr.2017.12.010.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766756/

(...) Today, the FDA issued a Drug Safety Communication alerting health care providers and patients of the increased risk of serious side effects when combining these particular MAT drugs with benzodiazepines – often prescribed to treat anxiety, insomnia, or other conditions – and how to address these risks while continuing to maintain patients on MAT. (FDA – U.S. Food&Drug Administration, 20.09.2017)

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm576752.htm

Pregabalin as adjunctive therapy in benzodiazepine discontinuation.

Caniff K, Telega E, Bostwick JR, Gardner KN.

Am J Health Syst Pharm. 2018 Jan 15;75(2):67-71. doi: 10.2146/ajhp160712.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29317396

"I love having benzos after my coke shot": The use of psychotropic medication among cocaine users in downtown Montreal.

Motta-Ochoa R, Bertrand K, Arruda N, Jutras-Aswad D, Roy É.

Int J Drug Policy. 2017 Aug 18;49:15-23. doi: 10.1016/j.drugpo.2017.07.012.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/28826127

Reasons for Benzodiazepine Use Among Persons Seeking Opioid Detoxification.

Stein MD, Kanabar M, Anderson BJ, Lembke A, Bailey GL.

J Subst Abuse Treat. 2016 Sep;68:57-61. doi: 10.1016/j.jsat.2016.06.008.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955948/

Benzodiazepines and risk of all cause mortality in adults: cohort study.

Patorno E, Glynn RJ, Levin R, Lee MP, Huybrechts KF.

BMJ. 2017 Jul 6;358:j2941. doi: 10.1136/bmj.j2941.

http://www.bmj.com/content/358/bmj.j2941

Risk factors associated with benzodiazepine use among people who inject drugs in an urban Canadian setting.

Tucker D, Hayashi K, Milloy MJ, Nolan S, Dong H, Kerr T, Wood E.

Addict Behav. 2016 Jan;52:103-7. doi: 10.1016/j.addbeh.2015.10.002.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644450/